FY2026 EPS Forecast for SCYNEXIS Decreased by Analyst

SCYNEXIS, Inc. (NASDAQ:SCYX) – Research analysts at Brookline Capital Markets cut their FY2026 earnings per share (EPS) estimates for shares of SCYNEXIS in a report released on Thursday, November 5th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn ($3.48) per share for the year, down from their previous estimate of ($1.60). Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for SCYNEXIS’s current full-year earnings is ($1.60) per share. Brookline Capital Markets also issued estimates for SCYNEXIS’s Q4 2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at $0.76 EPS, FY2027 earnings at ($0.37) EPS, FY2028 earnings at ($0.83) EPS, FY2029 earnings at ($4.55) EPS and FY2030 earnings at ($6.20) EPS.

SCYNEXIS (NASDAQ:SCYX) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.01. The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million.

SCYX has been the topic of several other reports. Guggenheim reissued a “buy” rating and set a $33.00 price target (up from $24.00) on shares of SCYNEXIS in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SCYNEXIS in a research note on Thursday, October 22nd. Finally, Wall Street Zen lowered shares of SCYNEXIS from a “hold” rating to a “sell” rating in a report on Saturday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $33.00.

SCYNEXIS Price Performance

Shares of SCYX opened at $3.50 on Tuesday. SCYNEXIS has a 1 year low of $3.28 and a 1 year high of $9.12. The stock has a 50 day simple moving average of $4.36 and a two-hundred day simple moving average of $5.47. The firm has a market cap of $34.83 million, a P/E ratio of -2.43 and a beta of 1.15.

Hedge Funds Weigh In On SCYNEXIS

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wealth Effects LLC purchased a new position in SCYNEXIS during the second quarter valued at $56,000. Empowered Funds LLC purchased a new stake in shares of SCYNEXIS in the second quarter worth $63,000. Velan Capital Investment Management LP purchased a new stake in shares of SCYNEXIS in the second quarter worth $163,000. BlackRock Inc. bought a new position in shares of SCYNEXIS during the second quarter valued at $169,000. Finally, Renaissance Technologies LLC increased its holdings in shares of SCYNEXIS by 27.6% during the first quarter. Renaissance Technologies LLC now owns 224,640 shares of the company’s stock valued at $206,000 after acquiring an additional 48,640 shares in the last quarter. 54.37% of the stock is owned by institutional investors.

Key Stories Impacting SCYNEXIS

Here are the key news stories impacting SCYNEXIS this week:

• Positive Sentiment: Brookline Capital Markets kept its Buy rating and raised its FY2027 EPS forecast to a loss of $0.37 from a loss of $0.80, while projecting $0.76 EPS in Q4 2027. That more optimistic 2027 estimate may offer some support to sentiment.
• Positive Sentiment: SCYNEXIS is targeting year-end for a kidney-drug trial, while its antifungal program advances. The article headline signals potential development milestones, though it provides no trial results. SCYNEXIS Targets Year-End Kidney Drug Trial as Antifungal Program Advances
• Negative Sentiment: Brookline cut its FY2026 EPS estimate to a loss of $3.48 from a loss of $1.60 and lowered its Q4 2026 forecast to a loss of $0.43 from a loss of $0.24. It also reduced FY2028 and FY2029 estimates, suggesting weaker expectations in several periods despite its Buy rating.
• Negative Sentiment: Wall Street Zen downgraded SCYNEXIS to Sell, adding a bearish analyst view. SCYNEXIS (NASDAQ:SCYX) Cut to Sell at Wall Street Zen

About SCYNEXIS

SCYNEXIS, Inc is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls.

SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis.